Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry
ConclusionsThe study highlights the need to consider different age groups separately in elderly RA care. Among patients aged 75 years and older, abatacept and anti-IL-6R antibodies showed the highest continuation rates, suggesting their potential suitability and efficacy for this specific age cohort. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 19, 2023 Category: Rheumatology Source Type: research
Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 Patients
ConclusionFunctional impairment, QoL, and depressive symptoms are mutually interdependent. Early diagnosis of PsA and initiation of anti-inflammatory therapy are essential to avoid long-term damage, disability, and mental health complications. However, despite therapy many patients with PsA, and especially female patients, report a substantial residual disease burden due to their psoriatic disease which will need to be addressed by a more patient-centered approach. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 15, 2023 Category: Rheumatology Source Type: research
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
ConclusionsGuselkumab treatment provided durable and meaningful improvements in axial symptoms and disease activity in substantial proportions of patients with active PsA and imaging-confirmed sacroiliitis.Trial RegistrationClinicaltrials.gov NCT03158285. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 11, 2023 Category: Rheumatology Source Type: research
Targeting DORIS Remission and LLDAS in SLE: A Review
AbstractRemission is the established therapeutic goal for patients with systemic lupus erythematosus (SLE) and is currently defined by the widely adopted Definition Of Remission In SLE (DORIS) criteria. Attainment of remission is rare in the clinical setting, thus an alternative, pragmatic treatment target of low disease activity, as defined by the Lupus Low Disease Activity State (LLDAS), provides a less stringent and more attainable treatment goal for a wider proportion of patients compared with DORIS remission. Randomized controlled trials and real-world analyses have confirmed the positive clinical benefits of achievin...
Source: Rheumatology and Therapy - October 5, 2023 Category: Rheumatology Source Type: research
Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still ’s Disease Treated with IL-1 and IL-6 Inhibitors: A Meta-analysis and Single-Center Experience
ConclusionsIn patients with AOSD, the manifestation of MAS is influenced by multiple causative factors. Consequently, the administration of TCZ should be approached with caution, particularly in patients exhibiting elevated inflammatory markers.Trial RegistrationThis study was registered with the Clinical Trial Registry of the University Hospital Medical Information Network (Japan) as UMIN000049243. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - October 4, 2023 Category: Rheumatology Source Type: research
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial
We describe the first international, prospective, double-blind, placebo-controlled trial to evaluate the safety and efficacy of B-cell depletion for flare prevention in IgG4-RD (MITIGATE).MethodsThe study was designed by an international panel of physicians with expertise in IgG4-RD. Critical trial design decisions included the selection of participants, definition of clinically meaningful primary and secondary endpoints, accommodation of standard of care, and development of flare diagnostic criteria. The study is approved for conduct in 22 countries.Planned OutcomesThe primary efficacy endpoint is time from randomization ...
Source: Rheumatology and Therapy - October 4, 2023 Category: Rheumatology Source Type: research
Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
ConclusionsThis PMSS investigated the safety and effectiveness of baricitinib in clinical practice in China. No VTE/MACE or new safety signals were reported and there was promising effectiveness, supporting the use of baricitinib in Chinese patients with moderate-to-severe active RA.Trial RegistrationEU PAS Register: EUPAS34213. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 28, 2023 Category: Rheumatology Source Type: research
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients
ConclusionThis real-world data can better inform clinicians about baricitinib effectiveness and drug survival when prescribing treatment for patients with RA across different subpopulations. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 27, 2023 Category: Rheumatology Source Type: research
Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China
ConclusionsPatients with SLE require long-term administration of HCQ, but blood levels vary widely between individuals. Studying the factors influencing the blood HCQ and DHCQ concentrations and optimizing the dose according to individual characteristics might help to improve the efficacy of HCQ.Trial RegistrationChiCTR2300070628. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 27, 2023 Category: Rheumatology Source Type: research
Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
ConclusionsFilgotinib did not lead to substantial changes in BMI, and BMI did not appear to affect the efficacy of filgotinib.Trial RegistrationClinicalTrials.gov identifiers: NCT02889796, NCT02873936, NCT02886728, NCT03025308, NCT01888874, NCT01894516, NCT02065700. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 25, 2023 Category: Rheumatology Source Type: research
Association Between Mycophenolate Mofetil Use and Subsequent Infections Among Hospitalized Patients with Systemic Lupus Erythematosus: A Nested Case –Control Study
ConclusionsMMF use is associated with various type of infections in patients with SLE, particularly in those with longer use, older age, complications with comorbidities, and concomitant use of CYC or other immunosuppressants. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 24, 2023 Category: Rheumatology Source Type: research
A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis
ConclusionsIn this real-world cohort of patients with RA, treatment with upadacitinib was associated with early and significant improvement in RAPID3, pain, morning stiffness, and fatigue regardless of prior TNFi experience. Clinically meaningful improvement in RAPID3 patient-reported disease activity was observed as early as week 1, with continued improvement reported through week 12. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 20, 2023 Category: Rheumatology Source Type: research
Correction: Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA)
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 20, 2023 Category: Rheumatology Source Type: research
Systematic Literature Review of Real-World Evidence on Baricitinib for the Treatment of Rheumatoid Arthritis
ConclusionBaricitinib demonstrated effectiveness in the real-world setting with a consistent safety profile observed in clinical studies. Better persistence rates for baricitinib compared to bDMARDs with improvement in PROs were reported, although baricitinib-treated patients had RA with poor prognostic characteristics. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 16, 2023 Category: Rheumatology Source Type: research
Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis
ConclusionsIn each treatment group, MDA domains less frequently achieved were PtGA and pain, suggesting that “patient-driven domains” are still an unmet need.Due to the study design and the low number of patients in some groups, it is not possible to clearly define which MDA domain was achieved or not based on treatment; however, it seems that some differences could be present. If larger and prospective studies confirm our preliminary results, we could move toward a personalized/domain treatment approach in PsA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - September 16, 2023 Category: Rheumatology Source Type: research
